Your browser doesn't support javascript.
loading
Significant heightened methylation levels of RUNX3 gene promoter in patients with systemic lupus erythematosus.
Ehtesham, Naeim; Alesaeidi, Samira; Mohammad Zadeh, Dorita; Saghaei, Mozhdeh; Fakhri, Maryam; Bayati, Zahra; Esmaeilzadeh, Emran; Mosallaei, Meysam.
Affiliation
  • Ehtesham N; Department of Medical Genetics, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran.
  • Alesaeidi S; Department of Internal Medicine and Rheumatology, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohammad Zadeh D; Personalized Medicine and Genometabolomics Research Center, Hope Generation Foundation, Tehran, Iran.
  • Saghaei M; Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Fakhri M; Department of Rheumatology, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Bayati Z; Department of Genetics, Faculty of Sciences, Arak University, Arak, Iran.
  • Esmaeilzadeh E; Personalized Medicine and Genometabolomics Research Center, Hope Generation Foundation, Tehran, Iran.
  • Mosallaei M; Personalized Medicine and Genometabolomics Research Center, Hope Generation Foundation, Tehran, Iran.
Lupus ; 33(6): 547-554, 2024 May.
Article in En | MEDLINE | ID: mdl-38511579
ABSTRACT

OBJECTIVE:

Researchers are actively investigating new diagnostic and prognostic biomarkers that offer improved sensitivity and specificity for systemic lupus erythematosus (SLE). One area of interest is DNA methylation changes. Previous studies have shown a connection between the RUNX3 gene dysfunction and SLE. In this study, the focus was on examining the methylation level of the RUNX3 promoter in peripheral blood mononuclear cells (PBMCs) of SLE patients and healthy individuals.

METHODS:

A total of 80 individuals diagnosed with SLE from Iran, along with 77 healthy individuals, were included. The methylation levels of the RUNX3 gene in the extracted DNA were evaluated using the MethyQESD method. To determine the diagnostic effectiveness of the RUNX3 promoter methylation level, a receiver operating characteristic (ROC) curve was generated.

RESULTS:

The methylation of the RUNX3 promoter was found to be significantly higher in patients with SLE compared to healthy individuals (p < .001). This difference in methylation levels was observed between SLE patients and healthy individuals and between SLE patients with renal involvement and those without renal involvement (86.29 ± 10.30 vs 40.28 ± 24.21, p < .001). ROC analyses revealed that the methylation level of the RUNX3 promoter had a diagnostic power of 0.769 [95% CI (0.681-0.814)] for SLE. Additionally, there was a positive correlation between the RUNX3 methylation level and levels of creatinine and C4.

CONCLUSION:

The findings of this study emphasize the potential use of RUNX3 methylation levels in PBMCs of SLE patients as biomarkers for diagnosing the disease, predicting renal damage, and assessing disease activity.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukocytes, Mononuclear / Lupus Erythematosus, Systemic Limits: Humans Language: En Journal: Lupus Journal subject: REUMATOLOGIA Year: 2024 Document type: Article Affiliation country: Irán Country of publication: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukocytes, Mononuclear / Lupus Erythematosus, Systemic Limits: Humans Language: En Journal: Lupus Journal subject: REUMATOLOGIA Year: 2024 Document type: Article Affiliation country: Irán Country of publication: Reino Unido